BACKGROUND: Tumor necrosis factor superfamily ligands provoke a dilated cardiac phenotype signal through a common scaffolding protein termed tumor necrosis factor receptor-associated factor 2 (TRAF2); however, virtually nothing is known about TRAF2 signaling in the adult mammalian heart. METHODS AND RESULTS: We generated multiple founder lines of mice with cardiac-restricted overexpression of TRAF2 and characterized the phenotype of mice with higher expression levels of TRAF2 (myosin heavy chain [MHC]-TRAF2(HC)). MHC-TRAF2(HC) transgenic mice developed a time-dependent increase in cardiac hypertrophy, left ventricular dilation, and adverse left ventricular remodeling, and a significant decrease in LV+dP/dt and LV-dP/dt when compared with littermate controls (P<0.05 compared with littermate). During the early phases of left ventricular remodeling, there was a significant increase in total matrix metalloproteinase activity that corresponded with a decrease in total myocardial fibrillar collagen content. As the MHC-TRAF2(HC) mice aged, there was a significant decrease in total matrix metalloproteinase activity accompanied by an increase in total fibrillar collagen content and an increase in myocardial tissue inhibitor of metalloproteinase-1 levels. There was a significant increase in nuclear factor-κB activation at 4 to 12 weeks and jun N-terminal kinases activation at 4 weeks in the MHC-TRAF2(HC) mice. Transciptional profiling revealed that >95% of the hypertrophic/dilated cardiomyopathy-related genes that were significantly upregulated genes in the MHC-TRAF2(HC) hearts contained κB elements in their promoters. CONCLUSIONS: These results show for the first time that targeted overexpression of TRAF2 is sufficient to mediate adverse cardiac remodeling in the heart.
BACKGROUND:Tumor necrosis factor superfamily ligands provoke a dilated cardiac phenotype signal through a common scaffolding protein termed tumor necrosis factor receptor-associated factor 2 (TRAF2); however, virtually nothing is known about TRAF2 signaling in the adult mammalian heart. METHODS AND RESULTS: We generated multiple founder lines of mice with cardiac-restricted overexpression of TRAF2 and characterized the phenotype of mice with higher expression levels of TRAF2 (myosin heavy chain [MHC]-TRAF2(HC)). MHC-TRAF2(HC) transgenic mice developed a time-dependent increase in cardiac hypertrophy, left ventricular dilation, and adverse left ventricular remodeling, and a significant decrease in LV+dP/dt and LV-dP/dt when compared with littermate controls (P<0.05 compared with littermate). During the early phases of left ventricular remodeling, there was a significant increase in total matrix metalloproteinase activity that corresponded with a decrease in total myocardial fibrillar collagen content. As the MHC-TRAF2(HC) mice aged, there was a significant decrease in total matrix metalloproteinase activity accompanied by an increase in total fibrillar collagen content and an increase in myocardial tissue inhibitor of metalloproteinase-1 levels. There was a significant increase in nuclear factor-κB activation at 4 to 12 weeks and jun N-terminal kinases activation at 4 weeks in the MHC-TRAF2(HC) mice. Transciptional profiling revealed that >95% of the hypertrophic/dilated cardiomyopathy-related genes that were significantly upregulated genes in the MHC-TRAF2(HC) hearts contained κB elements in their promoters. CONCLUSIONS: These results show for the first time that targeted overexpression of TRAF2 is sufficient to mediate adverse cardiac remodeling in the heart.
Authors: Denice M Hodgson; Leonid V Zingman; Garvan C Kane; Carmen Perez-Terzic; Martin Bienengraeber; Cevher Ozcan; Richard J Gumina; Darko Pucar; Fergus O'Coclain; Douglas L Mann; Alexey E Alekseev; Andre Terzic Journal: EMBO J Date: 2003-04-15 Impact factor: 11.598
Authors: D Bryant; L Becker; J Richardson; J Shelton; F Franco; R Peshock; M Thompson; B Giroir Journal: Circulation Date: 1998-04-14 Impact factor: 29.690
Authors: Yasushi Sakata; Amanda L Chancey; Vijay G Divakaran; Kenichi Sekiguchi; Natarajan Sivasubramanian; Douglas L Mann Journal: Basic Res Cardiol Date: 2007-11-21 Impact factor: 17.165
Authors: Abhinav Diwan; Ziad Dibbs; Shintaro Nemoto; Gilberto DeFreitas; Blase A Carabello; Natarajan Sivasubramanian; Eric M Wilson; Francis G Spinale; Douglas L Mann Journal: Circulation Date: 2003-12-29 Impact factor: 29.690
Authors: Veli K Topkara; Kari T Chambers; Kai-Chien Yang; Huei-Ping Tzeng; Sarah Evans; Carla Weinheimer; Attila Kovacs; Jeffrey Robbins; Philip Barger; Douglas L Mann Journal: JCI Insight Date: 2016-04-06
Authors: Sarah Evans; Huei-Ping Tzeng; Deborah J Veis; Scot Matkovich; Carla Weinheimer; Attila Kovacs; Philip M Barger; Douglas L Mann Journal: JCI Insight Date: 2018-02-08